Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.41 |
| ▸ | PON1 | P27169 | 1/20 | 0.41 |
| ▸ | NQO1 | P15559 | 1/20 | 0.41 |
| ▸ | AIMP2 | Q13155 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21591566 | 0.84 | SMN1; SMN2 (0.55) | SMN1; SMN2GLASTING1ALDH1A1HPGD | |
| SCHEMBL21591455 | 0.84 | PON1 (0.55) | SMN1; SMN2GLASTING1ALDH1A1HPGD | |
| SCHEMBL11616224 | 0.82 | MAOB (0.56) | SMN1; SMN2MAOBGLASTING1PSMB5 | |
| SCHEMBL23900884 | 0.75 | GLA (0.75) | SMN1; SMN2GLASTING1ALDH1A1PON1 | |
| SCHEMBL20587880 | 0.74 | SMN1; SMN2 (1.00) | SMN1; SMN2GLASTING1ALDH1A1HPGD | |
| SCHEMBL11620092 | 0.74 | MAOB (0.46) | SMN1; SMN2MAOBALDH1A1HPGDTSHR | |
| SCHEMBL11869804 | 0.74 | POLB (0.59) | MAOBALDH1A1HPGDTSHRPOLB | |
| SCHEMBL11862946 | 0.73 | NQO1 (0.46) | SMN1; SMN2MAOBALDH1A1HPGDMAPT | |
| SCHEMBL18235035 | 0.72 | MAOB (0.44) | SMN1; SMN2MAOBGLASTING1ALDH1A1 | |
| SCHEMBL11622080 | 0.72 | MAOB (0.56) | MAOBPOLBPSMB5ALOX15ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12162863-B2 | Modulators of stimulator of interferon genes (STING) | Ryvu Therapeutics S.A. (PL) | 2024-12-10 | — | — | US | disclosed |
| US-20220402898-A1 | MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | Ryvu Therapeutics S.A. (PL) | 2022-12-22 | — | — | US | disclosed |
| US-20220402898-A1 | MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | Ryvu Therapeutics S.A. (PL) | 2022-12-22 | — | — | US | disclosed |
| EP-3807264-A1 | MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | Ryvu Therapeutics S.A. (PL) | 2021-04-21 | — | — | EP | disclosed |
| WO-2019238786-A1 | MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | Ryvu Therapeutics S.A. (PL) | 2019-12-19 | — | — | WO | disclosed |
| WO-2019238786-A1 | MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | Ryvu Therapeutics S.A. (PL) | 2019-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12162863-B2 | Modulators of stimulator of interferon genes (STING) | STING1, IRF3, CGAS | SMN1; SMN2 3753/4885MAOB 730/4885GLA 3166/4885 |
| US-20220402898-A1 | MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | STING1, IRF3, CGAS | SMN1; SMN2 3753/4885MAOB 730/4885GLA 3166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.